Lung Cancer
Conditions
Brief summary
To develop and investigate a novel radiotherapy technique for preserving lung function based on a map of lung function.
Interventions
DEVICEReal-time Position Management system
Standard of Care
DEVICEDiscovery ST multislice PET/CT scanner
Standard of Care
DEVICEInfinia Hawkeye SPECT/CT gamma camera
Standard of Care
DEVICEPinnacle3 treatment planning system
Standard of Care
DEVICESKYLight nuclear camera
Standard of Care
DRUGDTPA
1 mCi; inhalation
DRUGTECHNETIUM TC 99M MAA
3 mCi; iv
Sponsors
Billy W. Loo Jr.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eligible disease(s)/stage(s) AJCC Stage I, II, III or IV lung cancer of any histology to be treated using radiotherapy will be eligible for this study. Note that we will carefully consider the inclusion of cases with turbulent flow or greater flow velocities (Cabahug et al., 1996; Crawford et al., 1990) and COPD cases (Magnant et al., 2006) due to the impaction of aerosol particles in central airways. * Allowable type and amount of prior therapy. Any types and amounts of prior therapy will be allowed for this study. * Age restriction and/or gender/ethnic restrictions * Patients must be greater than or equal to 18 years of age. * There are no gender or ethnic restrictions. * Life expectancy restrictions - None. * ECOG or Karnofsky Performance Status * Not employed. Note that patients will need to be sufficiently healthy to undergo audiovisual (AV) biofeedback to generate high quality 4D-CT images. * Requirements for organ and marrow function None. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
Children (less than 18 years of age), pregnant women, Stanford employees or students, or prisoners will be excluded from this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The overall correlation between the 4D-CT and the SPECT ventilation images. | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| The difference between the local ventilation at simulation and during the treatment. Dose-volume or functional dose-volume metrics. The regression coefficient between the regional ventilation and time. The mean dose to the high-functional lung region. | 24 months |
Countries
United States
Outcome results
None listed